Autoimmune limbic encephalitis (Q84129): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| (One intermediate revision by the same user not shown) | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 09:29, 15 August 2026
Autoimmune limbic encephalitis is an immune mediated disease of the limbic system or medial temporal lobes. The basis of such autoimmunity remains unclear in many cases but may follow a variety of viral infections. Unlike paraneoplastic encephalitis, a tumour is not present. It typically manifests with rapidly progressive cognitive decline often with accompanying seizures although brainstem and basal ganglia involvement may occur. Patients may also complain of headache, irritability, sleep disturbance, delusions, hallucinations, agitation, and psychosis. Neurological symptoms may respond favourably to immunotherapy. Investigations may reveal mesial temporal lobe T2 signal abnormalities on MRI and an inflammatory spinal fluid. Associated neural autoantibodies include: neural antibodies targeting plasma membrane antigens they are effectors of injury (e.g. voltage gated potassium channel antibodies-LGI1 or CASPR2 subtypes).
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_1254443511 |
||
| English | Autoimmune limbic encephalitis |
Autoimmune limbic encephalitis is an immune mediated disease of the limbic system or medial temporal lobes. The basis of such autoimmunity remains unclear in many cases but may follow a variety of viral infections. Unlike paraneoplastic encephalitis, a tumour is not present. It typically manifests with rapidly progressive cognitive decline often with accompanying seizures although brainstem and basal ganglia involvement may occur. Patients may also complain of headache, irritability, sleep disturbance, delusions, hallucinations, agitation, and psychosis. Neurological symptoms may respond favourably to immunotherapy. Investigations may reveal mesial temporal lobe T2 signal abnormalities on MRI and an inflammatory spinal fluid. Associated neural autoantibodies include: neural antibodies targeting plasma membrane antigens they are effectors of injury (e.g. voltage gated potassium channel antibodies-LGI1 or CASPR2 subtypes). |
Statements
CID11:ID_1254443511
0 references
dki-india-ID_1254443511
0 references
Concluído
0 references
13 August 2026
0 references
